DexCom (NASDAQ:DXCM) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, ...

"JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth" was originally created and published by Medical ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Shares of DexCom slid after the company reported mixed third-quarter results that included disappointing new patient numbers and lower gross margin guidance. The stock fell 15% to $58.10 and is down ...

In a surprising turn of events, shares of Dexcom Inc. (NASDAQ:DXCM) took a nosedive in pre-market trading following the company’s decision to lower its full-year sales forecast for glucose monitoring ...

DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...